Vascular Endothelial Growth Factor Inhibitor

Vascular Endothelial Growth Factor Inhibitor therapy began with the landmark approval of AVASTIN (bevacizumab) by Roche in 2004, targeting metastatic colorectal cancer and later non-small cell lung cancer. This pioneering drug established VEGF inhibition as a viable therapeutic strategy. Subsequent years saw the development of LUCENTIS (ranibizumab) by Roche in 2006 and EYLEA (aflibercept) by Regeneron in 2011, which, while also VEGF inhibitors, demonstrated improved selectivity and efficacy in ophthalmic indications like wet AMD, marking an evolution in targeting specific VEGF isoforms or binding mechanisms. Individual drugs within the VEGF inhibitor class differentiate themselves through their specific targets, efficacy in head-to-head trials, and administration profiles. For instance, AVASTIN and its biosimilars (MVASI, ZIRABEV, VEGZELMA) are broadly approved for various cancers, administered intravenously. In contrast, LUCENTIS, EYLEA, and their respective biosimilars (BYOOVIZ, CIMERLI) and related agents like SUSVIMO and PAVBLU are primarily used in ophthalmology, administered via intravitreal injection, with EYLEA HD offering extended dosing intervals for wet AMD and DME. ZALTRAP, a fusion protein, also targets VEGF but has a distinct profile for colorectal cancer. Today, Vascular Endothelial Growth Factor Inhibitor drugs hold significant positions in both oncology and ophthalmology. In oncology, AVASTIN and its biosimilars remain standard-of-care options, particularly in combination therapies for metastatic colorectal and non-small cell lung cancers. In ophthalmology, EYLEA and LUCENTIS, along with their biosimilars, dominate the treatment landscape for wet AMD and related conditions, with newer formulations like EYLEA HD aiming to improve patient convenience. The emergence of biosimilars, starting with MVASI in 2017, has increased market competition and access.